CA3094551C - Composition pharmaceutique a liberation prolongee contenant de la fesoterodine et son procede de preparation - Google Patents
Composition pharmaceutique a liberation prolongee contenant de la fesoterodine et son procede de preparation Download PDFInfo
- Publication number
- CA3094551C CA3094551C CA3094551A CA3094551A CA3094551C CA 3094551 C CA3094551 C CA 3094551C CA 3094551 A CA3094551 A CA 3094551A CA 3094551 A CA3094551 A CA 3094551A CA 3094551 C CA3094551 C CA 3094551C
- Authority
- CA
- Canada
- Prior art keywords
- agents
- pharmaceutical composition
- active ingredient
- fesoterodine
- glycerol dibehenate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une composition pharmaceutique à libération prolongée destinée à être administrée par voie orale comprenant, comme principe actif, une quantité thérapeutiquement efficace de fésotérodine ou d'un sel, métabolite ou dérivé pharmaceutiquement acceptable de celle-ci, une quantité efficace de dibéhénate de glycérol utilisé comme agent stabilisant pour permettre d'empêcher la dégradation et d'améliorer la stabilité physico-chimique du principe actif dans la forme galénique finie, et au moins un excipient pharmaceutiquement acceptable utilisé comme agent de régulation de la vitesse de libération pour modifier/réguler la libération du principe actif dans la forme galénique finie.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2018/000223 WO2019206391A1 (fr) | 2018-04-26 | 2018-04-26 | Composition pharmaceutique à libération prolongée contenant de la fésotérodine et son procédé de préparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3094551A1 CA3094551A1 (fr) | 2019-10-31 |
| CA3094551C true CA3094551C (fr) | 2024-01-02 |
Family
ID=62530172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3094551A Active CA3094551C (fr) | 2018-04-26 | 2018-04-26 | Composition pharmaceutique a liberation prolongee contenant de la fesoterodine et son procede de preparation |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3784217A1 (fr) |
| CA (1) | CA3094551C (fr) |
| WO (1) | WO2019206391A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2023145486A1 (fr) * | 2022-01-28 | 2023-08-03 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101466371B (zh) | 2006-06-09 | 2011-10-05 | 施瓦茨制药有限公司 | 含非索罗定的稳定的药用组合物 |
| EP2508175A1 (fr) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Composition pharmaceutique contenant de la fésotérodine ou un sel ou un solvate de celle-ci |
| ES2674811T3 (es) * | 2012-07-02 | 2018-07-04 | Hetero Research Foundation | Composiciones estables de fesoterodina |
-
2018
- 2018-04-26 WO PCT/EP2018/000223 patent/WO2019206391A1/fr not_active Ceased
- 2018-04-26 CA CA3094551A patent/CA3094551C/fr active Active
- 2018-04-26 EP EP18729320.4A patent/EP3784217A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3094551A1 (fr) | 2019-10-31 |
| EP3784217A1 (fr) | 2021-03-03 |
| WO2019206391A1 (fr) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2652712C (fr) | Compositions pharmaceutiques stabilisees contenant de la fesoterodine | |
| JP5278708B2 (ja) | ナテグリニド含有親水性医薬製剤 | |
| JP2014141518A (ja) | 難溶性薬物の溶解性改善製剤 | |
| EP2603206B1 (fr) | Compositions pharmaceutiques contenant des antagonistes des récepteurs métabotropiques du glutamate 5 (mglu5) | |
| JP4457003B2 (ja) | 放出制御医薬組成物 | |
| EP2603207A2 (fr) | Compositions orales de blonanserin a liberation controlee | |
| JP2005533774A (ja) | ジバルプロエクスソジウムの放出遅延剤 | |
| KR20120014583A (ko) | 타르타르산 염 형태의 데스페소테로딘 | |
| CA3094551C (fr) | Composition pharmaceutique a liberation prolongee contenant de la fesoterodine et son procede de preparation | |
| WO2005084636A2 (fr) | Procede de preparation d'une composition pharmaceutique a liberation controlee de metoprolol | |
| US20100055177A1 (en) | Modified release composition of levetiracetam and process for the preparation thereof | |
| Kestur et al. | Excipients for conventional oral solid dosage forms | |
| WO2009016608A2 (fr) | Compositions pharmaceutiques de fénofibrate | |
| JP2022514040A (ja) | 耐酸性に優れたタムスロシン塩酸塩含有医薬組成物及びその製造方法 | |
| JP2013035824A (ja) | ドンペリドン口腔内崩壊錠 | |
| EP3764983B1 (fr) | Formulation à libération prolongée comprenant de l'acémétacine à libération in vitro bimodale | |
| US20220249479A1 (en) | Modified release formulation of a pyrimidinylamino-pyrazole compound, and methods of treatment | |
| EP2303233A1 (fr) | Forme galénique orale solide contenant l agent anti-plaquettaire clopidogrel et son procédé de préparation | |
| WO2019011393A1 (fr) | Composition pharmaceutique à libération prolongée contenant de la fésotérodine et procédé de préparation de cette dernière | |
| CN115804774B (zh) | 一种噁拉戈利的药物组合物，包含其的药物制剂，及其应用 | |
| JP7761403B2 (ja) | 水不溶性ポリマーコーティング顆粒、それを含む製剤、口腔内崩壊錠及びそれらの製造方法 | |
| EP3796904A1 (fr) | Compositions d'acémétacine à libération prolongée | |
| US20100285126A1 (en) | Pharmaceutical compositions of fenofibrate | |
| WO2025170558A1 (fr) | Formulation pharmaceutique orale solide comprenant de l'avatrombopag | |
| Kestur et al. | EXCIPIENTS ORAL SOLID FOR DOSAGE CONVENTIONAL FORMS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210608 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250130 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250130 |